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Abstract
Introduction SUPREMO is a phase 3 randomised trial
evaluating radiotherapy post-mastectomy for intermediate-
risk breast cancer. 1688 patients were enrolled from 16
countries between 2006 and 2013. We report the results of
central pathology review carried out for quality assurance.
Patients and methods A single recut haematoxylin and
eosin (H&E) tumour section was assessed by one of two
reviewing pathologists, blinded to the originally reported
pathology and patient data. Tumour type, grade and lym-
phovascular invasion were reviewed to assess if they met
the inclusion criteria. Slides from potentially ineligible
patients on central review were scanned and reviewed
online together by the two pathologists and a consensus
reached. A subset of 25 of these cases was double-reported
independently by the pathologists prior to the online
assessment.
Results The major contributors to the trial were the UK
(75%) and the Netherlands (10%). There is a striking dif-
ference in lymphovascular invasion (LVi) rates (41.6 vs.
15.1% (UK); p =\0.0001) and proportions of grade 3 car-
cinomas (54.0 vs. 42.0% (UK); p =\0.0001) on comparing
local reporting with central review. There was no difference
in the locally reported frequency of LVi rates in node-posi-
tive (N?) and node-negative (N-) subgroups (40.3 vs.
38.0%; p = 0.40) but a significant difference in the reviewed
frequency (16.9 vs. 9.9%; p = 0.004). Of the N- cases, 104
(25.1%) would have been ineligible by initial central reviewElectronic supplementary material The online version of this
article (doi:10.1007/s10549-017-4145-4) contains supplementary
material, which is available to authorized users.
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by virtue of grade and/or lymphovascular invasion status.
Following online consensus review, this fell to 70 cases
(16.3% of N- cases, 4.1% of all cases).
Conclusions These data have important implications for
the design, powering and interpretation of outcomes from
this and future clinical trials. If critical pathology criteria
are determinants for trial entry, serious consideration
should be given to up-front central pathology review.
Keywords Breast cancer  Radiation therapy  Clinical
trial  Pathology  Quality assurance
Introduction
BIG 2.04 SUPREMO is a phase III international MRC/
EORTC randomised trial evaluating post-mastectomy
radiotherapy for intermediate-risk breast cancer accruing
1688 patients from 16 countries between 2006 and 2013.
Intermediate risk was defined as either node-positive (N?)
(pN1) disease of any grade in tumours B5 cm diameter (T1
or T2), or T2 node-negative (N-) tumours that were either
grade 3 and/or showed lymphovascular invasion (LVi), or
T3N0 tumours, independent of pathological features. Trial
entry was determined locally based on local pathological
evaluation. Central pathology review was planned to be
carried out later for quality assurance and not to confirm or
reject trial entrants, retrospectively. This policy was
adopted to allow applicability of the results to the real-
world situation of daily clinical practice. To the best of our
knowledge, this is the first and largest report of pathology
quality assurance within an international randomised breast
radiotherapy trial recruiting across three continents (Eur-
ope, Asia and Australasia). We report the results of the
pathology review.
Methods
Patient data and pathology materials
All patient data including locally reported pathology were
recorded and held centrally in the SUPREMO Trial Office
at the Scottish Clinical Trials Research Unit (SCTRU),
NHS Scotland in Edinburgh, UK. If multiple operations
had been performed, all reports were obtained. A require-
ment for trial entry was the submission of a representative
haematoxylin and eosin (H&E) stained section of the
tumour or a paraffin block from which an H&E could be
made centrally. For patients treated with neo-adjuvant
systemic therapy, the initial pre-treatment biopsy tissue
was used. Because of local tissue governance regulations
central pathology review was restricted to hospitals from
France, Germany, Japan, the Netherlands, Poland,
Switzerland, Spain, Turkey, the UK, and one centre each in
Australia, China and New Zealand.
Central pathology review
The two reviewing pathologists (JT & AH) were sent in
batches of 25, a single anonymised H&E section for each
patient identified by the SUPREMO Trial Number only.
The H&E section was usually recut rather than an original
because the majority of patients had also consented to
future translational studies. Data were recorded as follows:
tumour type; histological grade (Bloom and Richardson as
modified by Elston and Ellis 1991) [1]; and presence or
absence of lymphovascular invasion (LVi). Reviewing
pathologists were blinded to all patient data including
locally reported pathology and node status. The patholo-
gists are specialist breast pathologists working in large UK
centres (Edinburgh and Leeds). The reviewing pathologists
reported LVi according to UK reporting guidelines [2].
Pathology quality assurance
Data were analysed as follows:
1. Completeness of data.
2. Differences between reporting profiles of reviewing
pathologists and local reporting.
3. Discrepancies between local pathology reporting and
central review.
Analysis was limited to those discrepancies which
would have changed a patient’s eligibility to enter
the trial, i.e. a difference of overall grade or LVi
which was critical to the inclusion of patients in the
N- group.
The original H&E section from the discrepant cases
which had been reviewed previously by one of the
pathologists was scanned at 940 magnification
using the Aperio ScanScope slide scanner (Aperio
Technologies, Vista, CA) and was then viewed on
line by both pathologists simultaneously, and a
consensus was reached re grade and LVi. The
pathologists were blinded to their original
diagnoses.
6 Centre of Population Health Sciences, Edinburgh University
Medical School, Edinburgh EH8 9AG, UK
7 Edinburgh Cancer Centre, Western General Hospital,
Edinburgh EH4 2XU, UK
8 Ontario Institute for Cancer Research, Toronto,
ON M5G0A3, Canada
9 Beatson Oncology Centre, Gartnavel Campus,
Glasgow G12 0YN, UK
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4. Comparison of Nottingham Prognostic Index (NPI) in
N? and N- subgroups.
The NPI for the two subgroups was calculated from
the tumour size and number of positive nodes as
reported locally and the histological grade [3]. Two
calculations were made using the reported grade and
the grade from central review.
Statistical analysis
Comparison of proportions was made using a Chi squared
test. Groups were compared using the Mann–Witney
U Test. A two-sided p value of\0.05 was deemed sig-
nificant. Statistical calculations and charts were made with
Analyse-it  v2.11 for Excel .
Results
Completeness of data
Patient enrolment and exclusions from this QA study are
summarised in Fig. 1. 1688 patients were enrolled in the
trial, and 44 patients were of unknown nodal status at the
time of this analysis and were excluded from this study.
Primary systemic chemotherapy patients
26 patients were treated with primary systemic
chemotherapy, 12 N? and 14 N-. The primary systemic
chemotherapy patients were included in the study group. A
separate analysis of the study group with the 26 primary
systemic patients excluded shows no significant difference
in proportions of grade 3 cases or LVi.
Reporting profiles by nationality of treating site, of
reviewing pathologists and differences between central and
local reporting:
The data relating to nationality of treating site are
summarised in Table 1. This is limited to the top 7 (of 16)
countries submitting patients accounting for 97% of the
trial population. The two major contributors were the UK
(75%) and the Netherlands (10%). The presence of LVi
was reported locally in 41.6% of UK cases and 28.2% of
Dutch cases. The difference is significant (p =\0.001).
On central review, the frequency of LVi in the two coun-
tries was 15.1 and 19.2%, respectively. The difference is
not significant (p = 0.23). There were 161 different ran-
domising centres individually submitting between 1 and 70
cases (median 7 cases).
The overall data relating to the N? and N- subgroups
is summarised in Table 2. There were 1214 N? patients
and 430 N- patients. The LVi rate as reported locally was
Fig. 1 Flow diagram for
Pathology QA for SUPREMO
Trial
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high in both N? and N- groups (39.6 vs 38.2%) and
showed no significant difference (p = 0.40). Following
central review, however, LVi was significantly different for
the two groups (16.9 vs. 9.9%) (p = 0.004). 58 of the 708
patients who were reported locally as not showing LVi
were shown to have LVi on central review (8.2%). There
were similar significant differences between the overall
frequency of grade 3 carcinomas as locally reported
(52.7%) compared with central review (41.9%)
(p = 0.003).
Of the 1688 patients entered into the trial, 1382 had an
H&E section available for review. The two reviewing
pathologists evaluated 409 and 973 sections, respectively.
The centrally reported grade and LVi profile for the two
pathologists and as reported locally are summarised in
Table 3. The two reviewing pathologists show similar
reporting profiles, and there is no evidence of case selec-
tion bias between the two reviewed subsets.
A detailed breakdown of reviewed and reported LVi for
all patients, and those cases reviewed centrally against both
reported and reviewed grade is shown in Supplementary
Tables 1a and 1b, respectively. There is a striking differ-
ence in LVi rates on comparing local reporting with central
review across all grade groups.
Prognostic equivalence of N1 and N2 subgroups
The NPIs as calculated from reported grades for N? and
N- subgroups are shown in the box plots Fig. 2, and the
data for reported and reviewed subgroups are summarised
in Supplementary Table 2. Both the reported and reviewed
NPIs in the N? subgroup are significantly higher than the
N- subgroups (both p =\0.0001) with large numbers of
cases in the poor prognosis (NPI[ 5.4) group [30 and
23%, respectively (N?) compared with\1% (N-)]. The
reported and reviewed NPIs in the N- subgroup fall almost
Table 1 Reporting profiles by country of trial entry
No Reviewed % Node Pos % Reported Reviewed
Grade 3 (%) LVi (%) Grade 3 (%) LVi (%)
UK 1248 1064 85.3 73.0 54.6 41.2 42.4 15.1
Netherlands 175 154 88.0 76.0 52.0 28.4 39.6 19.5
China 60 24 40.0 100.0 26.8 31.7 45.0 28.6
France 49 35 71.4 71.4 42.8 28.5 46.7 0.0
Spain 39 36 92.3 87.1 28.2 26.3 53.8 16.7
Australia 22 17 77.3 54.5 59.1 45.4 56.2 6.2
Poland 20 18 90.0 65.0 28.6 46.1 27.8 0.0
Others (9 countries) 56 34 60.7 80.4 49.0 40.0 31.6 5.0
Total 1669 1382 82.8 74.6 52.7 39.3 41.9 15.1
Table 2 Reporting of Grade 3
carcinomas and LVi by
reviewing pathologists and
locally in N? and N-
subgroups
Node positive Node negative
Grade 3 Lvi Grade 3 Lvi
Reported Reviewed Reported Reviewed Reported Reviewed Reported Reviewed
Number 496 326 481 162 362 219 158 35
% 40.8% 33.7% 39.6% 16.9% 87.4% 64.2% 38.2% 9.9%
Table 3 Overall reporting profile of the two reviewing pathologists and local reporting by Grade, tumour type and LVi
Grade (No/%) Type
1 % 2 % 3 % NST % Lobular % Other % Lymphatic Invasion? Y (%)
Path 1 63 15.5 162 39.9 140 34.5 248 66 21 5.6 87 23.3 51 (14.2)
Path 2 57 5.8 479 49.7 409 42.5 857 89 61 6.3 45 4.7 147 (15.5)
Local 103 6.2 650 38.9 858 51.4 1155 87 91 6.8 89 6.7 639 (38.3)
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entirely (98 and 95%, respectively) within the intermediate
prognostic range (NPI 3.4–5.4).
In both the N? and N- subgroups, the mean NPI was
significantly lower following review [4.70 vs. 4.60 (N?)
and 4.53 vs. 4.48 (N-)] (p =\0.0003 and\ 0.0001,
respectively).
Numbers of discrepant cases
Because pathology criteria were used to determine eligi-
bility for the N- group, potentially ineligible cases inevi-
tably fell in this group following a pathology QA exercise
on the grounds of neither being grade 3 nor showing LVi
(114 cases, 95 from the UK).
Numbers of cases per reviewing pathologist and reasons
for discrepancy:
Pathologist 1—29/409 (7%) cases: 14 cases LVi; 12
cases grade; 3 cases both
Pathologist 2—85/873 (10%) cases: 33 cases LVi; 47
cases Grade; 15 cases both
Of these 114 cases, 108 were scanned satisfactorily and
were available for review online by the two pathologists.
23 cases were upgraded on review from grade 2 to 3, and a
further 12 cases were agreed to show LVi. Therefore, 32%
of cases originally deemed ineligible by initial central
review were deemed eligible following joint discussion.
Cross-over reporting
25 cases were re-reported from slides by the two patholo-
gists independently. There was complete agreement on
grade in 20 cases (80%). 5 cases showed grade 2/3 dis-
agreements (20%). There was no evidence of grade bias by
either pathologist. 2 cases showed disagreement about LVi
(8%).
Discussion
Implications for patient eligibility for SUPREMO
and other clinical trials
Following a central review of pathology variables in the
SUPREMO Trial population, we identified 19% of N-
patients who would, if central pathology data were used, be
ineligible for the trial. Whilst the total number of cases
deemed ineligible by central review was low, it represents
a significant sub-group of the N- patients.
The non-eligible rate for our N- subgroup raises
concerns about the interpretation of outcomes from this
trial, particularly in the N- subgroup. Our data raise
questions about whether clinical trials need to be pow-
ered to accommodate significant minorities of patients
actually being ineligible or should they reflect practice in
the real world? In the ARTemis trial, the principal
pathological end point was confirmed by review of
pathology reports by the clinical investigators [4]. This
was because the trial was powered on the basis of full
recruitment, whereas slide retrieval was anticipated to be
85% of entrants at best. If it is decided that pathological
central review is the desired way to assess a particular
outcome, then the powering of the trial will need to be
adjusted to allow for this estimated retrieval rate of
around 85%.
In the SUPREMO trial, N- patients were required to
have either grade 3 carcinomas or LVi or both, whereas
N? patients were not. This was an attempt to ensure a
degree of prognostic equivalence between the two groups.
We compared the two groups looking at their respective
NPIs to test this assumption and found a significant dif-
ference between them. We appreciate that the NPI does not
include LVi as a factor and so this tool only examined this
issue partially.
Fig. 2 Box plots showing
distribution of NPI scores for
the N? and N- subgroup as
originally reported
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Critical evaluation of this central pathology review
The following issues need to be considered in the inter-
pretation of our data:
1. We reviewed a single recut H&E section and not the
original tumour sections available to the local pathol-
ogists. We accept fully that this will lead inevitably to
a lower reviewed LVi frequency compared with the
local frequency. The availability of a single H&E for
central review is certainly an important issue in
explaining the lower LVi frequency on central review
but does not explain the lack of difference in local
reporting between N? and N- subgroups.
2. In the original trial protocol, specific instructions were
not given as to how LVi should be reported. The
reviewing pathologists did not meet to discuss how this
aspect of the review should be carried out but simply
followed the UK guidelines as per their normal
practice. In view of fact that 75% of SUPREMO cases
were from the UK, we would expect these cases to
have been reported according to standard UK practice.
It is notable that SUPREMO Trial cases were not
entered into the trial until the MDM where the case
was discussed—therefore after it had been reported. It
follows that on average in the UK patients with
intermediate-risk breast cancer (whether N? or N-)
have an LVi frequency of[40%. This is not in line
with the reviewing pathologists’ experience.
3. When the reviewing pathologists carried out the cross-
over review, they upgraded LVi status on 20% of
cases. If this were extrapolated across the whole N-
group (assuming that the status change was always in
one direction), then the LVi frequency would rise from
15 to 19%. That is still a long way from 41%.
4. The proximity of reporting profiles of the two review-
ing pathologists is remarkably close, and it is of
concern that the reviewing pathologists consistently
found a substantially lower rate of LVi than was
locally reported where the bias was in favour of the
presence of LVi rather than its absence. There is a
trend in our data of increased frequency of LVi with
increasing grade, but there is no difference between the
frequency of reported LVi in the N? and N- groups,
whereas this was a consistent finding by the two
reviewing pathologists. In the Nottingham case series,
there were strong correlations between nodal status and
tumour grade and LVi where 12% of grade 1
carcinomas and 40% of grade 3 carcinomas showed
LVi [5]. Two further large studies of LVi in N- breast
cancer have shown overall rates of 19.5 and 19%,
respectively [6, 7]. In the Uppsala, radiotherapy trial
for Stage 1 breast cancer where all tumour slides were
reviewed LVi was recorded in 22% of cases [8].
5. Our data also show significant differences between the
frequency of grade 3 carcinomas as reported locally
(53%) and following central review (42%). The central
review figure is very close to that reported in the
Nottingham series of 3255 patients where grade 3
carcinomas accounted for 43% of cases overall [5].
6. From a logistical point of view, the QA process for this
trial was labour-intensive. The two reviewing pathol-
ogists (AH & JT) are currently carrying out the
pathology QA for the LORIS trial [9] where patho-
logical eligibility criteria are confirmed at the time of
diagnosis by near-real-time review of scanned images
on line. Using this approach all potential patients’
pathology is turned around within five working days
with no delay to the patient’s management pathway.
Consistency of reporting among pathologists
There is substantial variability in the grading consistency
of pathologists [10], although a recent study showed
moderate to good consistency for grades 1 & 3
(kappa = 0.7) [11] in a large review of the NHS Breast
Screening Programme EQA Scheme the kappa for grade
was lower at 0.48 [12]. The literature is, however, con-
flicting on consistency of reporting by generalist and spe-
cialist pathologists [13–15]. It is encouraging to note that
there were no major differences in the broad metrics of
reporting profiles between the major countries contributing
to this trial.
Comparability of the N1 and N2 subgroups
NPI has been tested extensively as a prognostic tool and
has been shown to correlate well with medium and long-
term outcomes [16, 17]. This trial was designed and
powered on the assumption that the presence of grade 3
histology and/or lymphatic invasion would render the N-
patients prognostically equivalent to those with N? dis-
ease. This will only be known when outcome data become
available when the trial reports.
Conclusion
This international study provides unique data comparing
local reporting and central review of pathology for a large
clinical trial in three continents. Pathology criteria were
critical for the inclusion of N- patients and central review
even after arbitration suggest that up to 20% of this
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subgroup were ineligible for trial entry. The study raises
questions about design of clinical trials, particularly how
they are powered, the methodology of central pathology
review and the role of digital technology in supporting this
process. Consistency in pathology reporting between Eur-
ope and China provides a sound platform for collaboration
in clinical trials requiring multinational accrual.
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